<?xml version="1.0" encoding="UTF-8"?>
<p id="Par37">In Japan, a phase I/II study (TB-BC010088 study) involving patients with recurrent or refractory CD30-positive HL or sALCL was conducted by Takeda Bio Development Center Limited from October 2011 [
 <xref ref-type="bibr" rid="CR11">11</xref>]. Based on the results of the TB-BC010088, SG035–0003, and SG035–0004 studies as the main studies, a new drug application of SGN-35 was submitted by Takeda Pharmaceutical Company Limited. SGN-35 (proprietary name: ADCETRIS) was approved for patients with recurrent or refractory CD30-positive HL or ALCL. The administration method/dosage is as follows: for adults, brentuximab vedotin (gene recombinant) at 1.8 mg/kg (body weight) should be intravenously infused every 3 weeks. If necessary, the dose should be decreased in accordance with the patient's condition.
</p>
